Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
October 12, 2022
From Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
From Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
From Benzinga
What This News Means for Merck
October 01, 2022
From Motley Fool
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
From Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
From Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022
From Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
September 27, 2022
From Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
September 23, 2022
From Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
From Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
September 19, 2022
From Benzinga
From Benzinga
From Benzinga
A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know
September 12, 2022
From Benzinga
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
September 08, 2022
From Motley Fool
No More Free COVID-19 At-Home Tests, Federal Government Says
August 29, 2022
From Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
From Benzinga
From Benzinga
From Benzinga
OTC Markets' Most Active Securities Sees A Shake-up In July
August 16, 2022
From Benzinga
FDA Approves Expanded Use Of Roche's Influenza Treatment
August 12, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
August 03, 2022
From Benzinga
From Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
